Cortisol as a predictor of psychological therapy response in depressive disorders:Systematic review and meta-analysis by Fischer, Susanne et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1192/bjp.bp.115.180653
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Fischer, S., Strawbridge, R., Herane Vives, A. R., & Cleare, A. J. (2017). Cortisol as a predictor of psychological
therapy response in depressive disorders - a systematic review and meta-analysis. British Journal of Psychiatry,
210(2), 105-109. [180653]. DOI: 10.1192/bjp.bp.115.180653
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 15. Dec. 2017
1 
 
Running title 
Cortisol predicts psychological therapy response 
 
 
Cortisol as a predictor of psychological therapy response in depressive 
disorders – systematic review and meta-analysis 
 
 
Susanne Fischer, Rebecca Strawbridge, Andres Herane Vives & Anthony J. Cleare 
 
King’s College London, Institute of Psychiatry, Psychology & Neuroscience, Department of 
Psychological Medicine, Centre for Affective Disorders, London, United Kingdom 
 
Abstract: 141 words 
Text: 3159 words 
2 Figures 
2 Supplementary tables 
 
 
 
 
 
 
Corresponding author: Susanne Fischer, PhD, King’s College London, Institute of Psychiatry, 
Psychology & Neuroscience, Department of Psychological Medicine, 
Box PO74, 103 Denmark Hill, London SE5 8AF, United Kingdom 
Tel: +44 20 7848 5305 
E-mail: susanne.fischer@kcl.ac.uk 
2 
 
 
Abstract 
Background 
Many patients with depressive disorders demonstrate resistance to psychological therapy. A frequent 
finding is hypothalamic-pituitary-adrenal (HPA) axis alterations. As cortisol is known to modulate 
cognitive processes, those patients may be less likely to profit from psychological therapy.  
Aims 
To conduct a systematic review and meta-analysis on cortisol as a predictor of psychological therapy 
response. 
Method 
The Cochrane Library, EMBASE, MEDLINE, and PsycINFO databases were searched. Records were 
included if they looked at patients with any depressive disorder engaging in psychological therapy, 
with a pre-treatment cortisol and a post-treatment symptom measure. 
Results 
Eight articles satisfied our selection criteria. The higher the cortisol levels before starting psychological 
therapy, the more symptoms depressed patients experienced at the end of treatment and/or the 
smaller their symptom change. 
Conclusions 
Our findings suggest that depressed patients with elevated HPA functioning are less responsive to 
psychological therapy. 
 
Declaration of interests 
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Introduction 
Psychological therapies are amongst the most effective treatments for depressive disorders, with most 
evidence focusing on cognitive-behavioural therapy (CBT; 1). However, around 50% of patients do not 
respond to psychotherapeutic interventions (1). Upon repeated non-response to a number of 
treatment modalities, those patients are sometimes referred to as “treatment-resistant” patients. The 
illness course of this subgroup is most often relapsing or chronic (2), high levels of disability and 
mortality are common (3), and these patients make up the largest proportion of direct (e.g., treatment) 
and indirect (e.g., lost productivity; 4, 5) costs. Amongst the most salient features of depressive 
disorders are alterations in the hypothalamic-pituitary-adrenal (HPA) axis, one of the major stress-
responsive systems. Hypercortisolism, i.e., high circulating levels of cortisol, potentially due to 
impaired negative feedback sensitivity, is a common finding in depression (6, 7). It is noteworthy that 
cortisol modulates cognitive processes. In patients with major depression, cortisol seems to be related 
to cognitive impairment, and may thus explain symptoms such as concentration and memory 
difficulties (8). As a consequence, these patients may be less able to engage in learning processes, as 
occurring during psychological therapy. Based on these findings, it is conceivable that pre-treatment 
cortisol levels serve as a predictor of psychological therapy response in patients with depressive 
disorders. More specifically, we would hypothesise that patients demonstrating the most pronounced 
basal HPA axis alterations would be at risk of profiting less from the corrective learning experiences 
that are made during therapy. In the case of depression, this would mean that the higher a patient’s 
basal cortisol levels, the higher their level of depression would remain upon completing therapy. 
Similarly, the extent to which a patient shows HPA axis alterations following standardised 
neuroendocrine testing (stimulation or suppression tests), psychosocial stressors, or natural 
challenges such as awakening (“post-challenge cortisol”) would also likely be associated with poorer 
response. Our aim was to systematically review the literature on cortisol levels as a predictor of 
psychological therapy response and to quantify the strength of this relationship. 
 
Method 
Search strategy 
Relevant records were identified by one of the study investigators (SF) by systematically searching the 
Cochrane Library, EMBASE, MEDLINE, and PsycINFO databases from the first available year until 
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March 2015. We combined key words and subject headings in accordance with the thesaurus of each 
database and applied exploded subject headings. Our search string consisted of three components: 1) 
“cortisol” and synonyms, 2) “depressive disorder”, including synonyms and related terms, and 3) 
“psychological therapy” and synonyms. All searches were restricted to studies conducted in humans. 
No language restrictions were applied. 
 
Screening and selection procedure 
Identified records were screened regarding the following inclusionary criteria: 1) children, adolescent 
or adult outpatients or inpatients primarily suffering from any depressive disorder (i.e., major 
depressive disorder, persistent depressive disorder, or adjustment disorder with depressed mood) 
diagnosed according to DSM or ICD criteria, 2) any kind of pre-treatment cortisol assessment, and 3) 
psychological therapy (i.e., any treatment including at least one session of behavioural therapy, 
cognitive therapy, CBT, interpersonal therapy, psychodynamic therapy, or psychoanalysis delivered by 
a trained clinician) including a standardised post-treatment symptom measure. Comorbidity with 
mental disorders was not exclusionary, and neither was comorbidity with medical diseases or previous 
or current intake of medication. Studies delivering a combination of psychological and 
pharmacotherapy were excluded. Full-text articles were retrieved and checked for relevant analyses. 
The reference sections of all articles were then searched for additional records. 
 
Data extraction 
For each identified study one of the study investigators (SF) collected information about the first 
author, its year of publication, number of treated patients, their sex and age, their primary diagnosis, 
eligibility criteria (e.g., comorbidity and medication), study design, type and intensity of psychological 
therapy, pre-treatment levels of cortisol in hair, urine, saliva, or blood, post-treatment symptom scores 
of depression, and adjustment for covariates. This information is reported in the online supplementary 
Table 1. When multiple cortisol measures were reported, we favoured hair, urinary and salivary 
cortisol over plasma cortisol. This was to obtain a measure of free (i.e., unbound cortisol, as found in 
these media) rather than total cortisol (9). Moreover, we were interested in obtaining stable measures, 
which is why long-term (e.g. 3 cm hair cortisol) or aggregate indices (e.g. areas under the curve) were 
preferred over single time point assessments. Evening or afternoon measurements were to be 
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extracted in preference to morning levels, as due to the diurnal rhythmicity of cortisol inter-individual 
variability is lower later in the day (9). When psychological therapy response was assessed at multiple 
time points, the assessment closest to the last therapy session was selected. Symptoms of depression 
were chosen as outcome variables. Whenever studies used multiple symptom measures as outcome 
variables (e.g., different questionnaires assessing depression), an average effect size was calculated 
and extracted. Risk of bias was assessed by means of an adapted version of a quality tool that was 
used in an earlier meta-analysis on the role of cortisol in functional somatic syndromes (10). We used 
eight of the original nine items (item two was excluded due to non-applicability) and scored them using 
the same three-point scale (0-2). An additional item regarding the duration (weeks) and frequency of 
psychological therapy (number of sessions) was added; if both were stated, the study obtained a 
score of 2, if duration or intensity was stated, it was given a score of 1, and a score of 0 was given to 
those not giving any information about either of these characteristics. The complete checklist can be 
found in the supplementary Table 2. The maximum attainable quality score was 18. 
 
Effect size calculation 
To quantify the relationship between cortisol levels at baseline and psychological therapy response, 
correlation coefficients (r) were directly extracted by one of the study investigators (SF) or, if not 
available, calculated based on summary statistics, such as frequency tables, means, standard 
deviations, and sample sizes, or t values and sample sizes. This was done in in accordance with the 
procedures outlined by Lipsey and Wilson (11). In brief, statistics are converted into target effect sizes 
(in this case r) by means of mathematical formulas. For instance, the standardised mean effect size d 
is calculated based on means, standard deviations, and sample sizes and d in turn is converted into r 
using r = d/√(d2+a), with a being a correction factor that is used in the case of unequal sample sizes, 
and a = (n1+n2)2/n1n2 (12). Whenever correlation coefficients (r) were directly extracted, we used either 
correlations between cortisol values and symptoms of depression upon completion of treatment 
(controlled for pre-treatment levels of the same symptoms), or correlations between cortisol values 
and change in symptoms (delta values). We extracted data that were adjusted for relevant covariates 
rather than unadjusted data whenever possible. In cases where no or insufficient statistical 
parameters were reported regarding our research question, the authors were contacted. If we were 
unable to gather additional data from the authors and it was stated that no significant relationship 
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between pre-treatment cortisol levels and response to psychological therapy was found, we included a 
conservative effect size (ES) of 0 into our meta-analysis. 
 
Statistical analysis 
We calculated Fisher’s Zr and 95% confidence intervals (CI) for each study and weighed studies 
based on their sample size (11). Studies with an extreme ES (below or above two standard deviations) 
were to be excluded. Separate analyses for basal cortisol and post-challenge measures were 
conducted. An aggregated ES including a 95% CI was calculated for each analysis, using SPSS 21 
and the macros developed by David B. Wilson (http://mason.gmu.edu/~dwilsonb/ma.html). As 
significant statistical heterogeneity according to the Q and I2 statistics was predicted in all analyses, 
random rather than fixed effects models were considered appropriate (13). Sensitivity analyses were 
applied for studies with unclear eligibility. Publication bias was planned to be examined by visual 
inspection of funnel plots. In addition, Egger’s test (14) and a trim and fill procedure (15) were to be 
used for quantification of publication bias. 
 
Results 
Search results 
Our search yielded 25,991 records, of which 84 were considered potentially relevant based on their 
title or abstract. Of these, 76 were excluded because they were not original research (e.g., reviews), 
not conducted in depressed patients, did not assess cortisol levels, did not include any treatment at 
all, administered drugs as part of the treatment package, used specific interventions that did not meet 
our definition of psychological therapy (e.g., aerobic exercise), were retrospective (e.g., compared 
cortisol levels of treatment-resistant patients to healthy controls), or did not report predictor analyses. 
In one study, patients and healthy controls or patients receiving different kinds of treatments had been 
collapsed for statistical analyses (16). As the data set of this study was not available, it was excluded. 
In one paper, the authors stated that no relationship between pre-treatment cortisol levels and 
psychological therapy response was found (17). As no standardised regression coefficients were 
available with this report, we imputed an ES of 0 (95% CI [-0.512, 0.512]). Two reports were likely to 
have patient overlap according to the authors (18, 19), but as this could not be quantified, both were 
included into the initial analyses and assessed in sensitivity analyses. Another sensitivity analysis was 
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conducted excluding the study that used clomipramine in a pharmacological challenge test of the HPA 
axis (all remaining studies used the dexamethasone challenge test). In total, eight studies were 
eligible for data extraction. Tables 1 (online supplement) shows the characteristics of these studies. 
 
Systematic review and meta-analysis 
Eight studies were included with a total of 212 cases. Two studies focused on adolescents (17, 20) 
and one looked at older adults (21). The majority of patients had a major depressive disorder 
according to the DSM, and in most instances, patients had moderate to severe depression. Patients 
with major comorbid mental disorders, including substance use, psychotic, and bipolar disorders, were 
mostly excluded. By contrast, patients with comorbid medical diseases were often still considered 
eligible, that is, if their illness was unlikely to affect their depression, HPA axis functioning, or treatment 
itself. The handling of psychotropic medication was rather heterogeneous across studies: intake of 
medication was excluded a priori, discontinued shortly before treatment, or kept stable over the course 
of treatment. 
The distribution of outpatients to inpatients was 50:50. All patients received cognitive therapy 
or CBT, except for the two adolescents studies where patients were treated with interpersonal therapy 
(17, 20). Outpatients were treated on a weekly basis for a total duration of eight to 16 weeks. 
Inpatients had three to five sessions of psychological therapy per week, lasting between three and six 
weeks. Basal levels of cortisol were determined in urine, blood, or saliva. The earlier studies were 
primarily interested in post-challenge cortisol levels and used the dexamethasone suppression test to 
assess this. This test allows the assessment of negative feedback sensitivity by administering 1 mg of 
a synthetic analogue of cortisol; higher concentrations of cortisol on the day after dexamethasone 
administration indicate alterations (hyperactivity) in the HPA axis. Patients were often divided into non-
responders and responders. One study challenged the HPA axis by administering the tricyclic 
antidepressant clomipramine, and here, lower cortisol concentrations were considered maladaptive 
(22). The Beck Depression Inventory and Hamilton Rating Scale for Depression were the most 
frequently employed therapy response measures. Again, some studies divided patients into groups of 
non-responders and responders. 
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Quality scores ranged from 7 to 13 out of a maximum of 18 points. The quality of the 
diagnostic assessment, stating of eligibility criteria, the description of psychological therapy and the 
statistical reporting were very satisfactory in general. On the other hand, virtually no information on the 
duration of patients’ illness and on the blindness of therapists and assessors of treatment response to 
patients’ cortisol levels was provided. The description of HPA axis assessment and the handling of 
confounders varied greatly. 
Results were fairly consistent: Half of the studies found that patients with higher basal or post-
challenge cortisol levels retained higher levels of depression upon completion of psychological therapy 
(18, 20, 23, 24). Two more studies were in line with these findings, although only with regard to some 
of the employed cortisol and depression measures (19, 21). More specifically, in the study by Thase et 
al., only basal levels of cortisol (but not post-challenge levels) were associated with treatment 
response, whereas basal cortisol levels in the study by Holland et al. only predicted change in 
depression levels when the three used outcome scales were combined to create a global depression 
index. Two studies did not find any association between cortisol levels and psychological therapy 
response (17, 22). Subsequent meta-analysis confirmed the overall finding: a significant relationship 
between basal cortisol levels (five independent ES, mean ES = 0.264, 95% CI [0.047, 0.481]; Z = 
2.382, p = .017) and post-challenge cortisol levels (six independent ES, mean ES = 0.421, 95% CI 
[0.095, 0.748]; Z = 2.528, p = 0.012) and response to psychological therapy emerged, indicating that 
higher cortisol levels pre-treatment were associated with more severe symptoms post-treatment or 
smaller changes in symptoms (see Figures 1 and 2 for forest plots). 
 
- Insert Figures 1 and 2 here - 
 
Significant heterogeneity was present regarding post-challenge cortisol levels (Q = 15.22, p = 
0.010, I2 = 67.15%), but not regarding basal levels (Q = 5.55, p = .235; I2 = 27.93%). However, due to 
the low number of included studies, the latter result cannot be regarded as definitive evidence for the 
absence of heterogeneity. For the same reason, Egger’s test and the trim and fill procedure were not 
undertaken. Sensitivity analyses were conducted by repeating analyses without the study where an 
effect size had been imputed (17), without the study that was likely to have some degree of case 
overlap with a later report (18), and without the one using clomipramine to challenge the HPA axis 
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(22). Excluding the study that possibly overlapped with another included study rendered our previously 
significant association between basal cortisol levels and outcomes significant by trend only (four 
independent ES, mean ES = 0.215, 95% CI [-0.029, 0.460]; Z = 1.726, p = .084). However, the 
positive finding of post-challenge cortisol levels predicting treatment response remained significant 
and no other changes of our results occurred as a result of excluding the other two studies. 
 
Discussion 
The main finding of the present meta-analysis is that the higher the basal and post-challenge cortisol 
levels before starting psychological therapy, the more symptoms depressed patients experienced at 
the end of treatment and/or the smaller their symptom change. 
This finding is in line with our initial hypothesis that HPA axis alterations, in this case indicated 
by high cortisol levels, are associated with worse psychological treatment outcomes in depressed 
patients. Importantly, basal levels of cortisol were associated with response to psychological therapy 
by trend only when one study was excluded that had potential patient overlap with another study. As it 
was not possible to determine whether this overlap actually occurred or not, this finding needs to be 
interpreted with caution. Cortisol in response to the dexamethasone suppression test, on the other 
hand, did predict treatment response in the present meta-analysis. This is interesting from a clinical 
point of view, as the dexamethasone test offers the possibility of assessing HPA axis integrity in a 
highly standardised manner. In addition, the dexamethasone depression test can now be undertaken 
using salivary cortisol measures making it a more practical test that can be undertaken at home 
without the need for venepuncture or hospital attendance (13). Importantly, however, our findings may 
not be applicable to patients with atypical depression, who have been found to present with low rather 
than high cortisol values (7). 
One explanation for our findings is evidence that HPA axis alterations may be linked with 
cognitive functioning. According to this line of reasoning, the more pronounced a depressed patient’s 
HPA axis alterations, the more severe his/her cognitive impairment, which in turn renders him/her less 
capable of engaging in psychological therapy. Based on our findings, it may be sensible to combine 
psychological therapy with psychotropic medication, which specifically targets hypercortisolism, such 
as antidepressants (25) or anti-glucocorticoid agents (e.g., mifepristone; 26). However, considering 
the low overall number of published studies, the possibility of publication bias, the age of certain 
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studies, and the heterogeneity detected, further research on cortisol as a predictor of psychological 
therapy responses is clearly warranted before treatment suggestions can be made based on the 
findings reported here. 
Strong evidence suggests that HPA axis alterations in depression originate from experiences 
of childhood trauma and chronic stress (27, 28). Apart from direct effects on treatment efficacy via 
cognitive impairment, hypercortisolism may thus indicate a specific subgroup of patients with 
depression, and one that has its aetiology in earlier life trauma or chronic stress (29, 30). In fact, a 
recent meta-analysis showed that those depressed patients who reported childhood maltreatment had 
poorer responses across treatment modalities (31). Apart from the above-mentioned psychotropic 
agents, clinicians may therefore consider interventions that have a strong focus on trauma and/or 
interpersonal functioning, with the latter being an important source of chronic stress. Moreover, 
findings of a recent trial suggest that mindfulness-based cognitive therapy (MBCT) may be specifically 
useful for patients who report childhood trauma (32). Taken together, this line of evidence suggests it 
would be highly commendable for future studies on cortisol as a predictor of treatment response to 
stratify patients according to their levels of childhood trauma, and to test whether the findings we 
report here are driven by a specific subgroup of depressed patients. 
Several limitations need to be considered when interpreting our results. First, our search 
yielded very few suitable studies. As a result of this, publication bias could not be assessed. Second, 
in some studies, important information was not reported, such as whether the assessors of treatment 
response were blind to the subjects’ cortisol levels. Another point is that covariates (e.g., psychotropic 
medication, baseline levels of depression) influencing cortisol levels and/or its association with 
treatment response have not been consistently taken into account. Third, there was substantial 
heterogeneity in eligibility criteria, cortisol and treatment response assessment within the included 
studies. Unfortunately, the small number of studies prevented us from exploring which factors were 
most strongly related to positive findings. 
Taken together, our findings suggest that pre-treatment cortisol concentrations may predict 
responses to psychological therapy in patients with depression. Accumulating evidence suggests that 
there may be a subtype of depression that has its origins in early life stress, which could take its toll on 
stress-responsive bodily systems, such as the HPA axis, and in turn mediate some aspects of the 
treatment resistance seen in these patients. Hypothalamic-pituitary-adrenal axis markers are thus a 
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promising avenue in research on treatment resistance. More studies that address the research 
question outlined in this meta-analysis are warranted. Future research may consider using long-term 
measures of HPA axis functioning, such as finger nail or hair cortisol concentrations, that most 
accurately represent the patients’ pre-treatment state, controlling for confounding factors, in particular 
depression severity and childhood trauma, and using continuous response scores when evaluating 
treatment success. 
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Figure 1 Forest plot regarding the association between basal cortisol levels pre-treatment and 
psychological therapy response in patients with depressive disorders. Positive correlation coefficients 
mean that high pre-treatment levels of cortisol were associated with either higher scores on measures 
of depression post-treatment or with lower change scores (in the latter case, coefficients were inverted 
for illustrative purposes). When multiple cortisol measures were reported, urinary and salivary cortisol 
were favoured over plasma cortisol, aggregate indices over single time point assessments, and 
evening or afternoon measurements over morning levels. When multiple depression measures were 
used as outcome variables, an average effect size was calculated and extracted. The plot shows the 
correlation coefficients and 95% confidence intervals for each included study. 
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Figure 2 Forest plot regarding the association between post-challenge cortisol levels pre-treatment 
and psychological therapy response in patients with depressive disorders. Positive correlation 
coefficients mean that high pre-treatment levels of cortisol were associated with either higher scores 
on measures of depression post-treatment or with lower change scores (in the latter case, coefficients 
were inverted for illustrative purposes). When multiple cortisol measures were reported, urinary and 
salivary cortisol were favoured over plasma cortisol, aggregate indices over single time point 
assessments, and evening or afternoon measurements over morning levels. When multiple 
depression measures were used as outcome variables, an average effect size was calculated and 
extracted. The plot shows the correlation coefficients and 95% confidence intervals for each included 
study. 
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Table 1 Characteristics of included studies on cortisol as a predictor of psychological therapy response in patients with depressive disorders 
Study Sample Setting and 
treatment 
Cortisol measure 
before treatment 
Symptom measure 
after treatment 
Results Quality (points) 
Rush, 1982 N = 14 
Inclusionary criteria: major 
depressive disorder (Research 
Diagnostic Criteria), Hamilton 
Rating Scale for Depression Score 
≥ 14 
Exclusionary criteria: psychosis, 
bipolar disorder, concomitant major 
medical disorders, intake of 
barbiturates, meprobamate, 
reserpine, phenytoin, methyldopa, 
or glucocorticoids 
Outpatient 
Non-randomised 
trial 
Cognitive therapy 
Blood, 
dexamethasone 
administration at 
11.30 pm (1 mg or 2 
mg), subsequent 
measure at 4 pm 
Responders: Beck 
Depression Inventory 
score ≤ 9 
Five out of five non-suppressors (> 4 µg/dl) were 
non-responders, whereas eight out of nine 
suppressors were responders 
7 
Robbins, 1989 N = 38, mean age 15.6 (range:13-
17) 
Inclusionary criteria: major 
depressive disorder (DSM-III), 
significantly incapacitated by their 
symptoms, eligible for 
dexamethasone suppression test 
Exclusionary criteria: significant 
medical illness, intake of 
psychotropic medication within past 
two weeks before dexamethasone 
suppression test 
Inpatient 
Non-randomised 
trial 
Psychological 
therapy for at least 
six weeks, 
consisting of 
psychodynamically 
oriented 
interpersonal 
individual 
psychological 
therapy (three 
times per week), 
family therapy 
(once per week), 
Blood, 
dexamethasone 
administration at 11 
pm (1 mg), 
subsequent 
measures at 8 am, 4 
pm, 11 pm  
Responders: 
Schedules for 
Affective Disorders 
and Schizophrenia 
items on depression 
and anhedonia of < 3 
All seven non-suppressors (> 5 µg/dl) were non-
responders, whereas 18 out of 31 suppressors 
were responders 
11 
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group therapy 
(twice per week), 
and active 
cognitive-
behavioural 
therapeutic milieu 
McKnight, 1992 N = 22 (22f) 
Inclusionary criteria: female, age ≥ 
18 years, major depressive 
disorder (DSM-III), Depression 
Scale of Minnesota Multiphasic 
Personality Inventory score ≥ 29, 
Beck Depression Inventory score ≥ 
20, Depression Adjective Checklist 
≥ 18, Personal Beliefs Inventory 
score ≥ 3, willing to pay for blood 
tests, eligible for dexamethasone 
suppression test 
Exclusionary criteria: any other axis 
I disorder, suicidality, 
antidepressant or tranquilising 
medication within past two weeks, 
under care for the treatment of 
depression and missing statement 
from physician allowing 
discontinuation of treatment 
Outpatient 
Randomised trial 
Weekly one-hour 
sessions of 
cognitive therapy 
for eight weeks 
(vs. treatment with 
tricyclic 
antidepressants) 
Blood, 
dexamethasone 
administration at 
11.30 pm (1 mg), 
subsequent measure 
at 4 pm 
Beck Depression 
Inventory 
Depression Adjective 
Checklist 
Depression Scale of 
Minnesota 
Multiphasic 
Personality Inventory 
The ten non-suppressors (≥ 5 µg/dl) had higher 
scores on all symptom measures when compared 
to the twelve suppressors (adjusted for pre-
treatment symptom scores) 
12 
Thase, 1993 N = 22 
Inclusion: predominant major 
depressive disorder (DSM-III-R), 
Hamilton Rating Scale for 
Depression score > 14 
Exclusion: ill health, alcohol and 
drug intake within past two weeks 
Inpatient 
Non-randomised 
trial 
Daily sessions of 
cognitive-
behavioural 
therapy for four 
weeks, mean of 
Urine, three 
consecutive 24 h 
collections 
Beck Depression 
Inventory 
Hamilton Rating 
Scale for Depression 
Cortisol levels were positively associated with 
scores on both symptom measures (post-treatment 
scores were highly correlated with their change 
scores: r = .92 and .96, respectively) 
11 
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12.9 sessions 
Thase, 1996 N = 29 (13f, 16m), mean age 32.7 
(range: 18-54) 
Inclusionary criteria: age 18-70, 
major depressive disorder (DSM-
III-R), index episode < 2 years 
duration, Hamilton Rating Scale for 
Depression score ≥ 15 
Exclusionary criteria: history of 
alcoholism or drug abuse within 
past six months, history of manic, 
hypomanic, or psychotic episodes, 
mental retardation, history of 
comorbidity with any other axis I 
disorder, antisocial or borderline 
personality disorder, unstable 
medical condition that may cause 
depression or affect 
dexamethasone suppression test, 
unstable medication that may 
cause depression or affect 
dexamethasone suppression test, 
electroconvulsive therapy within 
past six months, past non-
response to cognitive-behavioural 
therapy, continuation of 
pharmacotherapy 
Inpatient 
Non-randomised 
trial 
Daily sessions of 
cognitive-
behavioural 
therapy for four 
weeks, mean of 
12.4 sessions 
Urine, three 
consecutive 24 h 
collections 
Blood, 
dexamethasone 
administration at 11 
pm (1 mg), 
subsequent 
measures at 8 am, 4 
pm, 11 pm 
Beck Depression 
Inventory 
Hamilton Rating 
Scale for Depression 
Urinary free cortisol levels were negatively 
associated with change in both symptom measures 
Mean post-dexamethasone plasma cortisol levels 
were not associated with change in either symptom 
measure 
10 
Kundermann, 
2009 
N = 18 (7f, 11m), mean age 36.8 
(SEM = 1.9) 
Inclusionary criteria: major 
depressive disorder (DSM-IV) 
Exclusionary criteria: comorbidity 
Inpatient 
Randomised trial 
Daily sessions of 
cognitive-
behavioural 
Blood, +30, +45, +60 
min after 
venepuncture, and 
+30, +45, +60, +90, 
+150 min after 
clomipramine 
administration 
Responders: 
Hamilton Rating 
Scale for Depression 
reduction of ≥ 50% 
Baseline cortisol levels (+60 min) did not differ 
between the nine non-responders and the nine 
responders (adjusted for age) 
Post-clomipramine cortisol output did not differ 
between the nine non-responders and the nine 
12 
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with any axis I or axis II disorder, 
suicidal tendencies, change of 
diagnosis during treatment, 
endocrine disorders, pregnancy or 
shift work within past three months, 
trans-meridian travel within past 
month, medication within past six 
days 
therapy 
(with/without sleep 
deprivation) for 
three weeks 
responders (adjusted for age) 
Gunlicks-
Stoessel, 2013 
N = 15 (13f, 2m), mean age 15.2 
Inclusionary criteria: age 12-17, 
major depressive disorder, 
dysthymic disorder, depressive 
disorder NOS, or adjustment 
disorder with depressed mood 
(DSM-IV), Children’s Depression 
Rating Scale revised score ≥ 36, 
Beck Depression Inventory II score 
≥ 14, Children’s Global 
Assessment Scale score ≤ 65, 
Conflict Behavior Questionnaire 
score ≥ 65 
Exclusionary criteria: substance 
abuse, bipolar disorder, thought 
disorder, eating disorder, conduct 
disorder, mental retardation, 
current risk for suicide, medical 
illness likely to interfere with 
treatment, concurrent treatment for 
depression, concurrent treatment 
with psychotropic medication or 
unstable medication for attention 
deficit hyperactivity disorder within 
the past three months 
Outpatient 
Randomised trial 
Weekly sessions 
of interpersonal 
therapy 
(with/without more 
involvement of 
parents) for 16 
weeks 
Saliva, baseline 
measure before 
discussion of an 
interpersonal conflict, 
subsequent 
measures +10, +20, 
+30 min 
Children’s 
Depression Rating 
Scale  – revised 
version 
Baseline cortisol levels were not associated with 
change in the symptom measure (alcohol abuse, 
medication, BMI, abuse, and time since awakening 
did not influence the analyses) 
Cortisol trajectories during the conflict were not 
associated with change in the symptom measure 
(alcohol abuse, medication, BMI, abuse, and time 
since awakening did not influence the analyses) 
11 
Holland, 2013 N = 54 (33f, 21m), mean age 70.2 
(SD = 7.5) 
Outpatient 
Non-randomised 
Saliva, two 
consecutive days at 
awakening, 5 pm, 9 
Beck Depression 
Inventory II 
Diurnal cortisol output was not associated with 
change in any of the symptom measures 
13 
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Inclusionary criteria: older adults, 
major depressive disorder, 
dysthymia, or adjustment disorder 
with depressed mood, Center for 
Epidemiologic Studies Depression 
Scale score ≥ 16 
Exclusionary criteria: dementia, 
active substance abuse, history of 
psychosis or mania, altering 
antidepressant use during study 
trial 
Twelve one-hour 
sessions of 
cognitive-
behavioural 
therapy for twelve 
to 16 weeks 
pm Center for 
Epidemiologic 
Studies Depression 
Scale  
Hamilton Rating 
Scale for Depression 
Structural equation modelling yielded a negative 
association between cortisol output and flatter 
slopes with change in depression (adjusted for age, 
gender, ethnicity, years of education, marital status, 
antidepressant usage, estrogen hormone 
replacement therapy, general mental and physical 
health) 
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Table 2 Quality tool to assess risk bias in studies investigating the relationship between pre-treatment 
cortisol levels and psychological therapy response in patients with depressive disorders (modified from 
Tak et al., 2011) 
1) Has the depressive disorder 
been reliably assessed and 
validated? 
According to ICD-10, DSM-IV, or DSM-5 by a trained clinician 
(2) 
Not according to ICD-10, DSM-IV, or DSM-5 or assessor not 
clearly established (1) 
Self-report or not clearly stated (0) 
2) Is the psychological treatment 
sufficiently described? 
Both treatment duration and session frequency are reported (2) 
Only treatment duration or session frequency is reported (1) 
No information about treatment duration or session frequency 
are given (0) 
3) Are the patients defined with in- 
and exclusion criteria? 
Medication use, comorbidity with medical diseases, comorbidity 
with other mental disorders, 3 stated (2) 
Medication use, comorbidity with medical diseases, comorbidity 
with other mental disorders, 1-2 stated (1) 
None stated or not clearly stated (0) 
4) Are disorder characteristics 
presented (duration and severity of 
major depressive episode)? 
Duration and severity of disorder are stated (2) 
Only duration or only severity is stated (1) 
None stated (0) 
5) Have the treating clinician and 
the person assessing treatment 
response been blind regarding pre-
treatment cortisol levels? 
Yes (2) 
Not clearly stated (0) 
6) Are methods for measuring 
cortisol clearly stated? 
Time of day, behaviour shortly prior to assessment, storage 
conditions, type of assay perfomed, repeated measurements, 
assessing compliance, 5-6 stated (2) 
Time of day, behaviour shortly prior to assessment, storage 
conditions, type of assay perfomed, repeated measurements, 
assessing compliance, 3-4 stated (1) 
Time of day, behaviour shortly prior to assessment, storage 
conditions, type of assay perfomed, repeated measurements, 
assessing compliance, 1-2 or none stated (0) 
7) Are the relevant statistics clearly 
described and presented? 
Both correlation coefficient and sample size available, frequency 
table available, or mean value and standard deviation available 
(2) 
Only sample size available or only mean value available (1) 
Relevant statistics not clearly stated (0) 
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8) Are potential confounders 
assessed?a 
Age, gender, body mass index, smoking, pre-treatment severity 
of depression, medication, physical exercise, 5-7 stated (2) 
Age, gender, body mass index, smoking, pre-treatment severity 
of depression, medication, physical exercise, 3-4 stated (1) 
Age, gender, body mass index, smoking, pre-treatment severity 
of depression, medication, physical exercise, 1-2 or none stated 
(0) 
9) Are the analyses adjusted for 
potential confounders?b 
Age, gender, body mass index, smoking, pre-treatment severity 
of depression, medication, physical exercise, 5-7 stated (2) 
Age, gender, body mass index, smoking, pre-treatment severity 
of depression, medication, physical exercise, 3-4 stated (1) 
Age, gender, body mass index, smoking, pre-treatment severity 
of depression, medication, physical exercise, 1-2 or none stated 
(0) 
aIn case of exclusion at item 3, consider confounder as assessed 
bIn case of exclusion at item 3 or no significant impact on statistical analyses, consider confounder as 
adjusted for 
 
